- Johns Hopkins pilot (Johnson, Garcia-Romeu, Cosimano, Griffiths 2014, n=15): 80% biologically verified abstinence at 6 months. 67% at 12 months. 60% at long-term follow-up.
- Methodological caveats: small sample, open-label, highly motivated self-selected participants, embedded in CBT structure. The 80% number is real but lives inside a specific context.
- Mechanism: 5-HT2A activation appears to disrupt the addiction loop and create a window in which behavioral change can land. Mystical-type experience scores correlate with quitting.
- Currently in Phase 2 multi-site trial at Hopkins, NYU, and elsewhere. Phase 3 expected.
- The dose alone does not quit smoking. The Hopkins protocol embeds psilocybin in a 15-week CBT framework. The drug is the catalyst; CBT is the structure.
Smoking and the cessation problem
Tobacco use kills more than 8 million people globally per year. Most smokers want to quit; about 5% who try without help succeed long-term. With pharmacotherapy (varenicline, nicotine replacement, bupropion) plus behavioral support, the rate roughly doubles. Still, most attempts fail.
The Hopkins psilocybin protocol claimed quit rates that, if confirmed in larger trials, would meaningfully outperform every existing first-line option.
Standard care
First-line: varenicline (Chantix) or nicotine replacement therapy plus behavioral counseling. Bupropion as second option. Combination NRT (patch + lozenge) outperforms single. Quitlines, group programs, and digital tools add modest benefit. Even with optimized protocols, sustained abstinence at 12 months tops out around 25-30%.
Why psychedelics for addiction
Several plausible angles, none yet fully nailed down:
- 5-HT2A and craving circuits. 5-HT2A receptors modulate prefrontal control over reward circuits in the ventral striatum. Acute activation may “loosen” the conditioned cue-reward loop.
- Mystical-type experience and meaning. Across psychedelic addiction trials, mystical-type experience scores predict outcome. Patients describe a perspective-shift on smoking as part of their identity, not just a behavior.
- Neuroplasticity window. Post-session 30-day plasticity supports new behavioral patterns being encoded. CBT during this window appears to land more easily.
- Self-efficacy. Survivors of a successful psilocybin session often report feeling capable of difficult change in a way pre-session they did not. This is a measurable behavioral therapy variable.
The Hopkins pilot, in context
| Study | Year | Design | Outcome |
|---|---|---|---|
| Johnson et al., JHU pilot | 2014 | Open-label, n=15, 2-3 doses + CBT | 80% biological abstinence at 6 months |
| Johnson et al., 12-month follow-up | 2017 | Same n=15 | 67% at 12 months, 60% long-term |
| Bogenschutz et al., NYU alcohol | 2015 | Open-label, n=10 alcohol use disorder | Significant reduction in heavy drinking days |
| Bogenschutz, NYU alcohol Phase 2 RCT | 2022 | RCT, n=93, 2 doses + therapy | 83% reduction in heavy drinking days vs 51% placebo |
| JHU smoking Phase 2 multi-site | In progress | RCT, larger | Pending |
The 80% number is real but comes from 15 highly motivated participants in an open-label structure. Phase 2 multi-site is the test of whether the effect scales. Until those results, “80%” is “80% in a specific context.”
The Hopkins protocol, briefly
15-week structure:
- Weeks 1-4: CBT-based smoking cessation prep, quit-date target, behavioral planning.
- Quit day: First psilocybin session (20 mg/70 kg, then 30 mg/70 kg). 6-8 hours, eyeshades, music, two-therapist support.
- Weeks 5-8: CBT continues. Second psilocybin session at week 8 (30 mg/70 kg).
- Weeks 9-15: CBT continues. Optional third dose for those still smoking. Biochemical verification (CO breath, cotinine).
- Follow-up: 6 and 12 months, biochemically verified.
This is psilocybin embedded in a CBT framework, not psilocybin instead of one.
Excluded from trial protocols:
Bipolar I or family history · Schizophrenia spectrum personal/family · Currently taking lithium, MAOIs · Severe cardiovascular disease, recent MI, uncontrolled hypertension · Pregnancy · Active suicidality · Current high-dose SSRI without supervised plan.
Risks specific to smokers
- Cardiovascular load compounds. Smokers have elevated cardiovascular risk baseline. Acute BP and HR spikes during psilocybin add load. Pre-screen with cardiology if any indication.
- Substitute substance use. Some quitters substitute one substance for another (smoking → vaping → cannabis). Set the protocol up to address all of them, not just nicotine.
- Withdrawal during the dose. Some patients experience nicotine withdrawal symptoms during or shortly after the session. Plan with clinical team for symptom management.
- Polysubstance histories. Many smokers have other addiction histories. The Hopkins protocol screens carefully; informal protocols often do not.
Who should not pursue this now
- Anyone unable to commit to the CBT structure. The dose alone does not quit smoking.
- Anyone with active severe cardiovascular disease.
- Anyone hoping to avoid evidence-based first-line cessation tools entirely.
- Anyone in unstable psychiatric state (active mania, psychosis, suicidality).
Integration practices
- CBT structureThe non-drug structure carries the change. Quit plan, trigger mapping, cue exposure, cognitive restructuring around identity-as-smoker.
- Movement30 min daily moderate cardio reduces craving intensity in cessation literature. Stack with the dose.
- SleepNicotine withdrawal disrupts sleep. Plan accordingly: melatonin, fixed schedule.
- Substitute behaviorsReplace cigarette breaks with breathwork, walks, water. See breathwork practices.
- Social supportTell people. Quit lines, partners, group programs. Social accountability outperforms most self-help.
- Track behaviorallyDays smoke-free. Cravings rated daily. CO breath test if you have access. Data cuts through magical thinking.
When to seek professional help
Smoking cessation has free public resources. CDC quitline 1-800-QUIT-NOW (US). NHS quit smoking program (UK). Most countries have similar. For mental health crisis: 988 (US), findahelpline.com.
